|
Siolta Therapeutics: Transforming Allergic Disease Prevention Through Microbial Biotherapeutics
Atopic diseases like eczema, asthma, and food allergies impact over 20% of children in the U.S., yet no treatments exist to prevent them. UCSF spinout Siolta Therapeutics, co-founded by Drs. Nikole Kimes and Susan Lynch of BCMM, is tackling this challenge with early-life gut microbiome-based therapies.
Building on groundbreaking research from the Lynch Lab, Siolta’s lead therapeutic candidate, STMC-103H, recently showed promising results in a Phase 2 clinical trial (ADORED). Infants treated with STMC-103H experienced significant reductions in risk for atopic dermatitis (64%) and food allergies (77%) compared to placebo groups.
Siolta’s work highlights the transformative potential of microbiome-targeted interventions to prevent disease, setting a new standard in neonatal and pediatric medicine.
Read the full article here.
|